Charlotte Kloft

5.7k total citations
207 papers, 4.1k citations indexed

About

Charlotte Kloft is a scholar working on Pharmacology, Infectious Diseases and Oncology. According to data from OpenAlex, Charlotte Kloft has authored 207 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Pharmacology, 40 papers in Infectious Diseases and 40 papers in Oncology. Recurrent topics in Charlotte Kloft's work include Antibiotics Pharmacokinetics and Efficacy (76 papers), Antimicrobial Resistance in Staphylococcus (26 papers) and Antibiotic Resistance in Bacteria (17 papers). Charlotte Kloft is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (76 papers), Antimicrobial Resistance in Staphylococcus (26 papers) and Antibiotic Resistance in Bacteria (17 papers). Charlotte Kloft collaborates with scholars based in Germany, Austria and United States. Charlotte Kloft's co-authors include Nele Plock, Jens Markus Borghardt, Wilhelm Huisinga, Ashish Sharma, Christian Joukhadar, Ulrich Jaehde, Robin Michelet, Sebastian G. Wicha, Alexander Staab and Markus Zeitlinger and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Charlotte Kloft

199 papers receiving 4.0k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Charlotte Kloft 1.4k 749 705 650 597 207 4.1k
Fritz Sörgel 1.8k 1.2× 1.0k 1.4× 723 1.0× 691 1.1× 1.3k 2.1× 144 5.4k
Francesco Scaglione 711 0.5× 991 1.3× 438 0.6× 516 0.8× 648 1.1× 195 4.5k
Stephen B. Duffull 1.5k 1.1× 921 1.2× 539 0.8× 512 0.8× 865 1.4× 278 8.3k
Michel Tod 737 0.5× 686 0.9× 492 0.7× 891 1.4× 564 0.9× 218 4.0k
Donald R. A. Uges 979 0.7× 944 1.3× 712 1.0× 857 1.3× 542 0.9× 143 4.2k
Evan J. Begg 1.3k 0.9× 414 0.6× 376 0.5× 356 0.5× 926 1.6× 145 4.5k
Markus Müller 1.7k 1.2× 637 0.9× 450 0.6× 1.4k 2.2× 714 1.2× 130 5.2k
Murray L. Barclay 1.1k 0.7× 1.7k 2.3× 571 0.8× 605 0.9× 2.0k 3.3× 197 9.0k
Martina Kinzig 1.2k 0.8× 332 0.4× 353 0.5× 319 0.5× 732 1.2× 104 2.9k
Jos G. W. Kosterink 730 0.5× 761 1.0× 1.4k 2.0× 1.2k 1.8× 1.0k 1.8× 146 5.2k

Countries citing papers authored by Charlotte Kloft

Since Specialization
Citations

This map shows the geographic impact of Charlotte Kloft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlotte Kloft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlotte Kloft more than expected).

Fields of papers citing papers by Charlotte Kloft

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlotte Kloft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlotte Kloft. The network helps show where Charlotte Kloft may publish in the future.

Co-authorship network of co-authors of Charlotte Kloft

This figure shows the co-authorship network connecting the top 25 collaborators of Charlotte Kloft. A scholar is included among the top collaborators of Charlotte Kloft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlotte Kloft. Charlotte Kloft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Klose, Martina, Simon Haefliger, Manuela Rabaglio, et al.. (2025). 35P TLD-1 – A novel liposomal doxorubicin formulation, in patients with advanced solid tumors: Final results of a multicenter, open-label, cross-over phase I study (SAKK 65/16). ESMO Open. 10. 104193–104193. 1 indexed citations
2.
3.
4.
5.
6.
Colombo, Ilaria, Simon Haefliger, Manuela Rabaglio, et al.. (2024). TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). European Journal of Cancer. 201. 113588–113588. 10 indexed citations
7.
Hessel‐Pras, Stefanie, et al.. (2024). PBTK model-based analysis of CYP3A4 induction and the toxicokinetics of the pyrrolizidine alkaloid retrorsine in man. Archives of Toxicology. 98(6). 1757–1769. 1 indexed citations
8.
Kloft, Charlotte, et al.. (2023). Cell‐level systems biology model to study inflammatory bowel diseases and their treatment options. CPT Pharmacometrics & Systems Pharmacology. 12(5). 690–705. 2 indexed citations
9.
These, Anja, Stefanie Hessel‐Pras, Jan G. Hengstler, et al.. (2023). PBTK modeling of the pyrrolizidine alkaloid retrorsine to predict liver toxicity in mouse and rat. Archives of Toxicology. 97(5). 1319–1333. 4 indexed citations
10.
Huisinga, Wilhelm, Niklas Hartung, Robin Michelet, et al.. (2023). C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework. Cancers. 15(22). 5429–5429. 8 indexed citations
11.
Stegemann, Miriam, Frieder Pfäfflin, Agata Mikołajewska, et al.. (2022). Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools. Antibiotics. 11(6). 758–758. 4 indexed citations
12.
Mikus, Gerd, et al.. (2022). Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism. Pharmaceutics. 14(3). 477–477. 10 indexed citations
13.
Groenland, Stefanie L., Alwin D. R. Huitema, Neeltje Steeghs, et al.. (2021). Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers. 13(24). 6281–6281. 14 indexed citations
14.
Michelet, Robin, Stefan Holdenrieder, Mark N. Wass, et al.. (2021). Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line. Cells. 10(4). 716–716. 9 indexed citations
15.
Stegemann, Miriam, Frieder Pfäfflin, Wilhelm Huisinga, et al.. (2021). Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing—A Translational Example for Intensive Care Units. Pharmaceutics. 13(12). 2128–2128. 2 indexed citations
16.
Melin, Johanna, Zinnia P. Parra‐Guillén, Robin Michelet, et al.. (2020). Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism. 105(4). e1729–e1740. 19 indexed citations
17.
Schroth, Werner, Thomas E. Mürdter, Robin Michelet, et al.. (2020). Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Clinical Pharmacology & Therapeutics. 108(3). 661–670. 21 indexed citations
18.
Carvalho‐Wodarz, Cristiane de Souza, et al.. (2020). Decoding (patho-)physiology of the lung by advanced in vitro models for developing novel anti-infectives therapies. Drug Discovery Today. 26(1). 148–163. 6 indexed citations
19.
Mikus, Gerd, et al.. (2019). Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metabolism Reviews. 51(3). 247–265. 53 indexed citations
20.
Neumann, Uta, et al.. (2017). Quality of compounded hydrocortisone capsules used in the treatment of children. European Journal of Endocrinology. 177(2). 239–242. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fritz Sörgel Breakdown of academic impact, for papers by Francesco Scaglione Breakdown of academic impact, for papers by Stephen B. Duffull Breakdown of academic impact, for papers by Michel Tod Breakdown of academic impact, for papers by Donald R. A. Uges Breakdown of academic impact, for papers by Evan J. Begg Breakdown of academic impact, for papers by Markus Müller Breakdown of academic impact, for papers by Murray L. Barclay Breakdown of academic impact, for papers by Martina Kinzig Breakdown of academic impact, for papers by Jos G. W. Kosterink
Rankless by CCL
2026